A Practical Guide to the Acute Management of DOAC-related Major Bleeds
This promotional workshop will provide a practical guide on the use of Ondexxya®(andexanet alfa) to support the acute management of patients on apixaban or rivaroxaban who present with a life-threatening bleed. The session will include an overview on the dosing and administration of the product as well as guidance on storage and integrating the use of Ondexxya within pathways.
This is a promotional workshop intended for UK healthcare professionals which has been organised and funded by AstraZeneca.
Ondexxya® has conditional approval for adult patients treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Delegates attending this session will gain an understanding of:
- The types of patients for whom the use of the product should be considered
- How to develop a guideline/protocol for local implementation
- Storage considerations
- Factors to consider in determining the dose
- How to reconstitute and administer the product
GB Prescribing information
NI Prescribing information
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033
GB-49818 | November 2023